Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209805%3A_____%2F13%3A%230000434" target="_blank" >RIV/00209805:_____/13:#0000434 - isvavai.cz</a>
Result on the web
<a href="http://jco.ascopubs.org/content/31/25/3091.full.pdf" target="_blank" >http://jco.ascopubs.org/content/31/25/3091.full.pdf</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1200/JCO.2012.47.8313" target="_blank" >10.1200/JCO.2012.47.8313</a>
Alternative languages
Result language
angličtina
Original language name
Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers
Original language description
Purpose is to determine whether adjuvant tamoxifen treatment for breast cancer (BC) is associated with reduced contralateral breast cancer (CBC) risk for BRCA1 and/or BRCA2 mutation carriers. Analysis of pooled observational cohort data, self-reported atenrollment and at follow-up from the International BRCA1, and BRCA2 Carrier Cohort Study, Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, and Breast Cancer Family Registry. Eligible women were BRCA1 and BRCA2 mutationcarriers diagnosed with unilateral BC since 1970 and no other invasive cancer or tamoxifen use before first BC. Hazard ratios (HRs) for CBC associated with tamoxifen use were estimated using Cox regression, adjusting for year and age of diagnosis, country, and bilateral oophorectomy and censoring at contralateral mastectomy, death, or loss to follow-up. Of 1,583 BRCA1 and 881 BRCA2 mutation carriers, 383 (24%) and 454 (52%), respectively, took tamoxifen after first BC diagnosis. There we
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
<a href="/en/project/ED2.1.00%2F03.0101" target="_blank" >ED2.1.00/03.0101: Regional Centre for Applied Molecular Oncology (RECAMO)</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2013
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Journal of Clinical Oncology
ISSN
0732-183X
e-ISSN
—
Volume of the periodical
31
Issue of the periodical within the volume
25
Country of publishing house
US - UNITED STATES
Number of pages
9
Pages from-to
3091-3099
UT code for WoS article
000330540600010
EID of the result in the Scopus database
—